Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD

Gut. 2022 Sep;71(9):1926-1928. doi: 10.1136/gutjnl-2021-326237. Epub 2021 Nov 24.

Authors

Rosanna Cannatelli¹, Francesca Ferretti², Stefania Carmagnola², Irene Maria Bambina Bergna², Maria Camilla Monico², Giovanni Maconi², Sandro Ardizzone²

Affiliations

¹ Gastroenterology and Digestive Endoscopy Unit, Department of Biochemical and Clinical Sciences 'L Sacco', University of Milan, ASST Fatebenefratelli Sacco, Milano, Italy cannatelli.rosanna@asst-fbf-sacco.it.
² Gastroenterology and Digestive Endoscopy Unit, Department of Biochemical and Clinical Sciences 'L Sacco', University of Milan, ASST Fatebenefratelli Sacco, Milano, Italy.

PMID: 34819330
DOI: 10.1136/gutjnl-2021-326237

No abstract available

Keywords: COVID-19; adverse drug reactions; inflammatory bowel disease.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Inflammatory Bowel Diseases* / drug therapy
Recurrence
Vaccination

Substances

COVID-19 Vaccines